Forkhead box P3 (Foxp3) + T regulatory (T reg ) cells maintain immune homeostasis and limit autoimmunity but can also curtail host immune responses to various types of tumors 1, 2 . Foxp3 + T reg cells are therefore considered promising targets to enhance antitumor immunity, and approaches for their therapeutic modulation are being developed. However, although studies showing that experimentally depleting Foxp3 + T reg cells can enhance antitumor responses provide proof of principle, these studies lack clear translational potential and have various shortcomings. Histone/protein acetyltransferases (HATs) promote chromatin accessibility, gene transcription and the function of multiple transcription factors and nonhistone proteins 3, 4 . We now report that conditional deletion or pharmacologic inhibition of one HAT, p300 (also known as Ep300 or KAT3B), in Foxp3 + T reg cells increased T cell receptor-induced apoptosis in T reg cells, impaired T reg cell suppressive function and peripheral T reg cell induction, and limited tumor growth in immunocompetent but not in immunodeficient mice. Our data thereby demonstrate that p300 is important for Foxp3 + T reg cell function and homeostasis in vivo and in vitro, and identify mechanisms by which appropriate small-molecule inhibitors can diminish T reg cell function without overtly impairing T effector cell responses or inducing autoimmunity. Collectively, these data suggest a new approach for cancer immunotherapy.
Foxp3 + T reg cells are pivotal to limiting host autoimmunity, but increased numbers of these cells within blood, tumors or lymphoid tissues of patients with cancers are often associated with poor prognosis 1, 2 . Experimental strategies to deplete T reg cells and promote antitumor immunity have transient efficacy, are nonspecific and often provoke autoimmunity [5] [6] [7] . Epigenetic approaches are being developed to pharmacologically modulate T reg cell functions, especially for treatment of autoimmunity 8 . In these approaches, deacetylase inhibitors increase acetylation of the key T reg cell transcription factor, Foxp3, and enhance Foxp3 + T reg cell suppressive function in vivo and in vitro [9] [10] [11] [12] , but there are limited data concerning HAT inhibitors and T reg cells. Of the three main HAT families (GNAT, p300-CBP and MYST 13 ), the p300-CBP family, and p300 in particular, can acetylate and stabilize Foxp3 protein expression in transfected cells 3, 4 .
Here we assess whether p300 targeting can affect T reg homeostasis or function and thereby promote antitumor immunity.
We conditionally deleted Ep300 (which encodes p300) in T reg cells by crossing Ep300 fl/fl and Foxp3 YFP-Cre mice (Supplementary Fig. 1a) . The resultant mice (hereafter Ep300 −/− mice) are deficient for Ep300 only in FoxP3 + cells. Ep300 −/− mice were born at expected Mendelian ratios, but from 10 weeks of age developed mild weight loss, dermatitis, lymphadenopathy and splenomegaly (Fig. 1a) , and focal mononuclear infiltrates in lung, liver and skin ( Fig. 1b and Supplementary Table 1) . They also showed mildly lower blood hematocrit and hemoglobin levels as compared to wild-type (WT) littermates (Supplementary Fig. 1b) . Compared to WT littermates, Ep300 −/− mice showed more basal T cell activation and production of proinflammatory cytokines, though overall T cell proportions were similar ( Fig. 1c and Supplementary Fig. 1c,d ). They also had higher serum IgG1 concentrations ( Supplementary  Fig. 1e) , and in contrast to WT littermates, ~20% developed autoantibodies (Supplementary Table 2 ). Microarray analysis showed that compared to WT T reg cells, Ep300 −/− T reg cells overexpressed proapoptotic genes ( Supplementary Fig. 2a,b) . Although Ep300 deletion did not affect CD4 + Foxp3 + cell numbers or expression of Foxp3 protein under basal conditions ( Fig. 1d and Supplementary Figs. 1 and 3a) , upon activation Ep300 −/− T reg cells had increased FasL mRNA (Fig. 1e,  Supplementary Fig. 3b ) and apoptosis (Fig. 1f) . Likewise, Ep300 −/− T reg cells adoptively transferred into immunodeficient but not immunocompetent mice survived for a shorter length of time compared to WT T reg cells (Fig. 1g) . The suppressive functions of Ep300 −/− T reg cells were modestly impaired and declined with age ( Supplementary Fig. 4a) . Hence, unlike scurfy mice, in which Foxp3 mutation disrupts DNA binding and causes lethal autoimmunity by 3 weeks of age, mice with Ep300 deletion have moderately affected T reg cell biology, comparable to that in other mice with conditional T reg cell targeting [14] [15] [16] .
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To assess T reg cell function in vivo, we transferred Ep300 −/− or WT T reg cells plus conventional effector T (T eff ) cells into immunodeficient mice. Compared to WT T reg cells, Ep300 −/− T reg cells were poor suppressors of homeostatic T eff cell proliferation ( Fig. 1h) and had shorter cell survival (Supplementary Fig. 4b ). In a second in vivo test of Ep300 deletion in T reg cells, we analyzed transplanted cardiac allografts. Immunodeficient recipients adoptively transferred with T eff cells alone, at the time of engraftment, developed acute rejection by 14 d after transplant, whereas mice receiving concurrent transfer of WT T eff and T reg cells maintained allografts long term (>100 d). However, mice given WT T eff cells and Ep300 −/− T reg cells rejected their allografts by 25 d after transplant (Fig. 1i) . In a third in vivo test, we transplanted hearts into WT or Ep300 −/− mice and treated the recipients with CD154-specific monoclonal antibody (mAb) plus donor splenocytes (DST) 17 . This potent form of co-stimulation blockade induced allograft tolerance in WT but not Ep300 −/− recipients (Fig. 1j) . Collectively, the data from our conditional targeting experiments show that p300 is important for normal T reg cell survival and suppressive function.
We next tested whether Ep300 deletion in T reg cells promotes antitumor immunity. Growth of TC1 lung adenocarcinomas, which express human papillomavirus E7 protein, was impaired in Ep300 −/− mice compared to WT mice (Fig. 2a) . Deletion of Ep300 did not affect lymphoid CD4 + Foxp3 + T reg cell numbers (data not shown) but did lower their expression of CD103, which is important for T reg cell recruitment to tumor sites 18, 19 , and increased the proportion of lymphoid CD8 + T eff cells and interferon-γ (IFN-γ) production (Fig. 2b) . Ep300 deletion also enhanced the beneficial effects of vaccination with adenovirally expressed E7 protein (Ad.E7) on TC1 tumor growth (Fig. 2c) . Likewise, Ep300 deletion impaired the growth of established ovalbumin (OVA) + AE17 mesotheliomas (Fig. 2d) . Compared to WT mice bearing tumors, Ep300 −/− mice bearing either tumor type had more mononuclear cell infiltration (Fig. 2e) , higher intratumoral CD8, granzyme B and IFN-γ mRNA levels and lower Foxp3 mRNA levels (Fig. 2f) ; immunohistology showed less T reg cell infiltration and high intratumoral CD8 + T eff cell numbers (Supplementary Fig. 5 ). Likewise, compared to WT tumor-bearing mice, AE17 tumor-bearing Ep300 −/− mice had fewer lymphoid CD4 + Foxp3 + CD103 + T reg cells but more CD8 + IFN-γ + and OVA-specific CD8 + T eff cells (Fig. 2g) . AE17 tumor-bearing Ep300 −/− mice also had low numbers of intratumoral T reg cells and low amounts of both total and acetylated Foxp3 protein, but high numbers of CD8 + OVA-specific T eff cells (Fig. 2h,i) . Lastly, deletion of Ep300 reduced T reg cell proliferation in tumor-bearing mice ( Fig. 2j and Supplementary Fig. 6a ). Hence, Ep300 conditional targeting can diminish T reg proliferation and accumulation within tumors and enhance antitumor immunity.
From a translational perspective, we wondered whether a smallmolecule nonpeptidic inhibitor of p300 (p300i), C646 (ref. 20) , would show similar utility to deletion of Ep300. We began with in vitro studies of the effects of p300i on Foxp3 and T reg cells and found that p300i decreased acetylation of Foxp3 by p300 ( Fig. 3a) and decreased T reg cell expression of Foxp3 mRNA and protein ( Supplementary  Fig. 6b ). T reg cells lacking Ep300 had lower levels of histone H3 acetylation at the Foxp3 promoter region compared to WT T reg cells, and p300i decreased the levels of acetylation at the Foxp3 promoter in WT but not Ep300 −/− T reg cells, indicating the specificity of this approach (Fig. 3b) . We also assessed effects of p300i on the transforming growth factor-β-induced conversion of naive CD4 + CD25 − T cells into Foxp3 + induced T reg (iT reg ) cells; iTreg cell development was impaired, especially in the first 2 d of culture (Fig. 3c) . Use of p300i reduced acetylation at the CNS1 enhancer, a region crucial to the process of peripheral conversion of conventional T cells into iT reg cells, but did not affect acetylation of histone H3 at the Foxp3 promoter (Fig. 3d) , which, in contrast to its role in thymic-derived T reg cells, is not important for iT reg conversion 21, 22 . Treatment of 293T cells with p300i inhibited Foxp3 transactivation (Fig. 3e) , and in vitro exposure of T reg cells to p300i decreased their suppressive activity (Fig. 3f) . Analysis of cells from WT C57BL/6 mice treated in vivo with p300i showed decreased acetyl-H3 accumulation at the Foxp3 promoter (Fig. 3g) , increased T reg cell apoptosis in WT but not in Ep300 −/− T reg cells (Fig. 3h) and decreased T reg cell suppressive function ( Fig. 3i and Supplementary  Fig. 6c ). However, p300i did not promote immune activation or affect T reg numbers (Supplementary Figs. 7a,b) . We used a parent-to-F1 adoptive transfer model involving alloantigeninduced T cell activation, proliferation and cytokine production 23 to assess the effects of p300i on conventional T cell functions in vivo. T cell activation and proliferation were comparable in groups receiving p300i or DMSO control (Supplementary Fig. 8a) . We next evaluated the effects of the p300i, C646, on T cell responses in cardiac allograft recipients 9 . Administration of C646 but not DMSO carrier abrogated T reg cell-dependent allograft survival, and we observed comparable effects using a peptidic p300i (Lys-CoA-Tat) 24 (Fig. 3j) . To eliminate the possibility that p300i affects graft survival by altering CD4 + CD25 − T cell function, we adoptively transferred CD4 + CD25 − T cells into immunodeficient recipients and treated them with p300i or DMSO control. In both groups, acute rejection developed similarly (Supplementary Fig. 8b ). We also tested whether p300i affected grafts directly by infusing p300i into isograft recipients; we did not observe any effects on long-term graft survival (>100 d survival, data not shown), which supports the idea that p300i acts preferentially on T reg cells. Moreover, p300i can prevent, or abrogate established, T reg cell-dependent immune responses, as shown by the ability of p300i, given from the day of surgery or from 30 d after transplant, to induce rejection in mice rendered tolerant by therapy with CD154 mAb and DST 17 (Fig. 3j) . Hence, p300i administration differentially affects T reg cells and T eff cells in vivo; notably, p300i use can decrease T reg cell suppressive function while simultaneously leaving intact protective T eff cell responses.
Lastly, we tested the effects of p300i on tumor growth. We found that p300i treatment significantly decreased growth of established TC1 tumors in normal (Fig. 4a) but not immunodeficient (Fig. 4b) mice. The compound probably reached tumor sites in the immunodeficient mice, as shown by decreased acetylation of histone H3 in tumor cells, and we observed no effect on the acetylation of p300-independent targets (for example, α-tubulin) (Fig. 4c) . p300i also significantly inhibited growth of established AE17 tumors in WT mice (Fig. 4d) . In both models, p300i promoted tumor infiltration by host mononuclear cells (Fig. 4e) , decreased intratumoral Foxp3 and increased CD8, granzyme B and IFN-γ expression (Fig. 4f) . Therapy with p300i also increased antigen-specific CD8 + OVA + T eff cells within OVA + AE17 tumors (Fig. 4g) . Collectively, our studies show that p300 targeting impairs T reg cells homeostasis and function and boosts antitumor immunity. In the steady state, Ep300 deletion in T reg cells favors a proapoptotic phenotype without affecting actual T reg cell frequency or number until subject to immune activation. Given our evidence of the importance of p300 to iT reg cell development and the knowledge that tumors can promote iT reg differentiation 25 , p300i may act not only by impairing the proliferation and function of existing T reg cells but also by limiting the ability of cancers to avoid immune destruction by promoting iT reg conversion 26 . In contrast to T reg cell-depletional therapies, p300i use in mice is reasonably safe as T reg numbers were unaffected, even in Ep300 −/− mice, and the treatment did not lead to severe autoimmunity. This ability of p300 targeting to modulate T reg cells, which probably results from affecting the acetylation and function of multiple transcription factors in T reg cells and not just that of Foxp3, is unexpected given the ubiquitous expression of p300. However, p300i therapy had no effects on tumor growth in immunodeficient mice and no untoward effects on conventional T cells or other immune cells (as seen, for example, in the parent-to-F1 and cardiac transplant experiments). Thus, we propose that p300 targeting Ad.E7 vaccination. 1 × 10 6 TC1 (E7 + ) cells were injected subcutaneously into the right flanks of WT and Ep300 −/− mice. One week later, mice bearing TC1 flank tumors (~100 mm 3 in size) were either left untreated, or vaccinated subcutaneously in the left flank (contralateral to the tumor) with 1 × 10 9 plaque forming units (PFU) of Ad.E7 vector, as previously described 32 . Three days following initial vaccination, mice received a booster vaccine of 1 × 10 9 PFU of Ad.E7 in the left flank. Tumor sizes were monitored twice per week.
OVA-tetramer staining. OVA-specific CD8 + T cells within tumors and spleens of experimental mice were determined by flow cytometry. Tumors were cut into small fragments and digested for 1 h at 37 °C with a cocktail of collagenase type I (0. 
